Trial
NCT03422523
Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
University Hospital Southampton NHS Foundation Trust
Collaborators
Hoffmann-La Roche
Condition
Diffuse Large B Cell Lymphoma
Intervention
Atezolizumab
Why stopped
Failure to reach pre-specified futility boundary
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-08-22